Efficacy and Safety of Low-Dose (0.2 mg) Dutasteride for Male Androgenic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Trial.

Ann Dermatol · 2025 · PMC12318778 · PMID 40736519

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

However, hair thickness exhibited an increasing trend. 3) Photographic assessment by the investigators and an independent expert panel Low-dose dutasteride significantly improved the hair growth change from baseline at week 24, as photographically assessed by the investigators ( p =0.0096).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.